Very Brief Blog: Friends of Cancer Research Holds 7th Annual "Blueprint" Precision Medicine Forum

On September 13, 2018, the Friends of Cancer Research will hold the 7th Annual "Blueprint for Breakthrough" forum Washington, DC, promoting precision medicine.

See the website here:

https://www.focr.org/events/7th-annual-blueprint-breakthrough-forum

It's a half day meeting (8:30-1:00).   It looks to me like registration is required but is free.

Scott Gottlieb MD, head of FDA, gives the opening address.   The first panel features presentations by Katherine Szarama PhD (CMS NCD), and Jonathan Hirsch (Syapse).   Reena Philip PhD, FDA molecular approvals, is also on this panel among others.   The second panel is on "supporting development of high quality diagnostic tests" and includes Timothy Stenzel MD PhD, the new head of diagnostics at FDA, as well as speakers from United Healthcare and Memorial Sloan-Kettering.

See the full agenda at the link above or cut/pasted here below the break (agenda as of 9/5).  The panel is supported and is co sponsored by Alexandria.

See some other fall precision medicine conference dates here.

Agenda for Friends of Cancer Research Forum, September 13, 2018.

(As of September 5, 2018).

Draft Agenda

8:30 AM - Registration and Breakfast

9:00 AM - Opening Remarks

• Ellen Sigal, Friends of Cancer Research
• Lynne Zydowsky, Alexandria Real Estate Equities, Inc.

9:05 AM - Keynote Address

• Scott Gottlieb, U.S. FDA

9:30 AM - Panel 1: Evidence to support clinical implementation and reimbursement
Moderator: Kavita Patel, Brookings Institution

Presentations:
Overview of CMS’ National Coverage Decision—Katherine Szarama, CMS
Mechanisms for Collecting Evidence Overtime—Jon Hirsch, Syapse

Panelists:
Alex Lazar, MD Anderson Cancer Center
Seth Sadis, Thermo Fisher Scientific
Girish Putcha, Palmetto GBA
John Simmons, Personal Genome Diagnostics

Jon Hirsch, Syapse
Katherine Szarama, CMS
Reena Philip, U.S. FDA

11:00 AM - Break

11:15 AM - Panel 2: Policy priorities for supporting development of high-quality diagnostic tests
Moderator: Kate Rawson, Prevision Policy

Panelists:
Eric Rubin, Merck

Florence Kurtilla, Patient advocate
Jennifer Malin, UnitedHealth Group
Mike Berger, Memorial Sloan Kettering Cancer Center
Representative, CMS
Timothy Stenzel, U.S. FDA
Troy Cox, Foundation Medicine

12:30 - Closing Remarks
Jeff Allen, Friends of Cancer Research